Loss of the tumor suppressor PML in human cancers of multiple histologic origins

Journal of the National Cancer Institute

Volumn 96, Issue 4, 2004, Pages 269-279

  Gurrieri, Carmela ^a   Capodieci, Paola ^a   Bernardi, Rosa ^a   Scaglioni, Pier Paolo ^a   Nafa, Khedoudja ^b   Rush, Laura J ^c   Verbel, David A ^a   Cordon Cardo, Carlos ^a   Pandolfi, Pier Paolo ^a  

^a Department of Obstetrics Gynecology   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA;

ADRENAL CORTEX CARCINOMA; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; COLON ADENOCARCINOMA; CONTROLLED STUDY; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE FUSION; GENE MUTATION; GERM CELL TUMOR; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; NORTHERN BLOTTING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SOLID TUMOR; STATISTICAL ANALYSIS; THYROID CARCINOMA; TUMOR CELL LINE;

EID: 1342291118     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh043     Document Type: Article

References (35)

1. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-215.
2. Zhong S, Salomoni P, Pandolfi PP. The transcriptional role of PML and the nuclear body. Nat Cell Biol 2000;2:E85-90.
3. Jensen K, Shiels C, Freemont PS. PML protein isoforms and the RBCC/TRIM motif. Oncogene 2001;20:7223-33.
4. Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolli PP. Role of SUMO-1-modified PML in nuclear body formation. Blood 2000;95: 2748-52.
5. Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honore N, Doubeikovsky A, et al. Role of promyelocytic leukemia (PML) sumoylation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 2001; 193:1361-71.
6. Kogan SC, Hong SH, Shultz DB, Privalsky ML, Bishop JM. Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood 2000;95:1541-50.
7. Pandolfi PP. In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene 2001;20:5726-35.
8. Rego EM, Wang ZG, Peruzzi D, He LZ, Cordon-Cardo C, Pandolfi PP. Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med 2001;193:521-9.
9. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, et al. PML is essential for multiple apoptotic pathways. Nat Genet 1998;20:266-72.
10. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, et al. Role of PML in cell growth and the retinoic acid pathway. Science 1998;279:1547-51.
11. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell 2002;108:165-70.
12. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. Embo J 2000;19:6185-95.
13. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, et al. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2000;2:730-6.
14. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000;406:207-10.
15. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 2000;14:2015-27.
16. Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, Zhong S, et al. PML-RARalpha alleviates the transcriptional repression mediated by tumor suppressor Rb. J Biol Chem 2001;276:43491-4.
17. Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, Shinagawa T, et al. Role of PML and PML-RARalpha in Mad-mediated transcriptional repression. Mol Cell 2001;7:1233-43.
18. Gambacorta M, Flenghi L, Fagioli M, Pileri S, Leoncini L, Bigerna B, et al. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am J Pathol 1996;149:2023-35.
19. Koken MH, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix MK, Sobczak-Thepot J, et al. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 1995;10:1315-24.
20. Zhang P, Chin W, Chow LT, Chan AS, Yim AP, Leung SF, et al. Lack of expression for the suppressor PML in human small cell lung carcinoma. Int J Cancer 2000;85:599-605.
21. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001;158:1245-51.
22. Lee CT, Capodieci P, Osman I, Fazzari M, Ferrara J, Scher HI, et al. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res 1999;5: 977-83.
23. Capodieci P, Magi-Galluzzi C, Moreira G Jr, Zeheb R, Loda M. Automated in situ hybridization: diagnostic and research applications. Diagn Mol Pathol 1998;7:69-75.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Stuart A. A test of homogeneity of the marginal distributions in a two-way classification. Biometrika 1955;42:412-6.
26. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. Cary (NC): SAS Institute; 1995.
27. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996;56:2649-54.
28. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
29. Mattsson K, Pokrovskaja K, Kiss C, Klein G, Szekely L. Proteins associated with the promyelocytic leukemia gene product (PML)-containing nuclear body move to the nucleolus upon inhibition of proteasome-dependent protein degradation. Proc Natl Acad Sci U S A 2001;98:1012-7.
30. Zhong S, Delva L, Rachez C, Cenciarelli C, Gandini D, Zhang H, et al. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat Genet 1999;23: 287-95.
31. Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F, Grosschedl R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 2001;15:3088-103.
32. Zhong S, Hu P, Ye TZ, Stan R, Ellis NA, Pandolfi PP. A role for PML and the nuclear body in genomic stability. Oncogene 1999;18:7941-7.
33. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
34. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998;90:1284-91.
35. Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001;116:637-46.